Next Article in Journal
Autophagy as a Potential Therapy for Malignant Glioma
Next Article in Special Issue
Immune Pathogenesis of COVID-19 Intoxication: Storm or Silence?
Previous Article in Journal
Lipoxygenase Inhibition Activity of Coumarin Derivatives—QSAR and Molecular Docking Study
Previous Article in Special Issue
Cancer Patients Have a Higher Risk Regarding COVID-19–and Vice Versa?
Review

Substance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and Complications

Department of Chemistry, New Jersey City University, Jersey City, NJ 07305, USA
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(7), 155; https://0-doi-org.brum.beds.ac.uk/10.3390/ph13070155
Received: 29 June 2020 / Revised: 15 July 2020 / Accepted: 16 July 2020 / Published: 18 July 2020
(This article belongs to the Special Issue COVID-19 in Pharmaceuticals)
As the world endures the coronavirus disease 2019 (COVID-19) pandemic, the conditions of 35 million vulnerable individuals struggling with substance use disorders (SUDs) worldwide have not received sufficient attention for their special health and medical needs. Many of these individuals are complicated by underlying health conditions, such as cardiovascular and lung diseases and undermined immune systems. During the pandemic, access to the healthcare systems and support groups is greatly diminished. Current research on COVID-19 has not addressed the unique challenges facing individuals with SUDs, including the heightened vulnerability and susceptibility to the disease. In this systematic review, we will discuss the pathogenesis and pathology of COVID-19, and highlight potential risk factors and complications to these individuals. We will also provide insights and considerations for COVID-19 treatment and prevention in patients with SUDs. View Full-Text
Keywords: COVID-19; SARS-CoV-2; coronavirus; substance use disorder (SUD); immunology; neuroinflammation; blood-brain barrier (BBB); hypothalamic–pituitary–adrenal (HPA) axis COVID-19; SARS-CoV-2; coronavirus; substance use disorder (SUD); immunology; neuroinflammation; blood-brain barrier (BBB); hypothalamic–pituitary–adrenal (HPA) axis
Show Figures

Figure 1

MDPI and ACS Style

Wei, Y.; Shah, R. Substance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and Complications. Pharmaceuticals 2020, 13, 155. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13070155

AMA Style

Wei Y, Shah R. Substance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and Complications. Pharmaceuticals. 2020; 13(7):155. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13070155

Chicago/Turabian Style

Wei, Yufeng, and Rameen Shah. 2020. "Substance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and Complications" Pharmaceuticals 13, no. 7: 155. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13070155

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop